TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32146720
Drug: SRP combined
Normalized name: SRP 299
DrugBank: SRP 299 (DB05440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP combined with laser therapy
Study: 32146720
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (SRP with and without laser therapy)
Study: 35500223
Drug: Metformin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin for 6 months
Study: 32584384
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injections (2 mg) monthly for 12 months
Study: 32584384
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injections (2 mg) quarterly for 12 months
Study: 32584384
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injections (2 mg) monthly or quarterly for 12 months
Study: 33563325
Drug: Azithromycin plus
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin plus standard of care (500 mg qd for 5 days)
Study: 33725432
Drug: ChAdOx1 nCoV-19
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV-19 vaccine (AZD1222), 5×10^10 viral particles, two doses 21 to 35 days apart
Study: 33725432
Drug: ChAdOx1 nCoV-19
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV-19 vaccine (AZD1222)
Study: 32493514
Drug: Tocilizumab (8mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8mg/kg body weight i.v. once, 12 mg/kg for patients <30kg BW, max 800 mg)
Study: 35194818
Drug: 6-week lifestyle
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week lifestyle medicine program consisting of five lifestyle factors
Study: 32142556
Drug: Rhythmic sensory
Normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rhythmic sensory stimulation (RSS) treatment with different parameters
Study: 32142556
Drug: Rhythmic sensory
Normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rhythmic sensory stimulation (RSS) treatment with different specifications
Study: 35331538
Drug: Melatonin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (10 mg/day for 24 weeks)
Study: 32121218
Drug: Low-dose DYM
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose DYM (100 mg)
Study: 32121218
Drug: High-dose DYM
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DYM (150 mg)
Study: 32121218
Drug: Low-dose DYM
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose DYM with TCR (100 mg + 50 mg)
Study: 32121218
Drug: High-dose DYM
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DYM with TCR (150 mg + 25 mg)
Study: 35848979
Drug: Acupuncture therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapies combined with swallowing training
Study: 33580200
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving ≥2 lines of treatment
Study: 34116700
Drug: Topical rVA576
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rVA576 eye drops, administered twice a day for 8 weeks
Study: 34116700
Drug: Topical rVA576
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rVA576 eye drops
Study: 33075444
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group (IG) - received a brochure with supplementary advice, tips, and monthly counselling on food texture introduction.
Study: 32369631
Drug: Prednisone Therapy
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone Therapy
Study: 32886447
Drug: Pregabalin (PGB)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin (PGB) monotherapy (150 mg twice daily)
Study: 32886447
Drug: Combined Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Combined Pregabalin (PGB) (150 mg twice daily) and Milnacipran (MLN) (50 mg twice daily)
Study: 32195927
Drug: Daily educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily educational text messages on diabetes and reminders for 6 months
Study: 32182123
Drug: Canagliflozin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (600 mg)
Study: 35197356
Drug: Volatile sedatives
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volatile sedatives
Study: 35197356
Drug: Intravenous sedatives
Normalized name: Sed-Max
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedatives
Study: 616173446
Drug: Regular recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular recommended HF therapy (including maximized beta-blockade)
Study: 35022014
Drug: Sertraline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (100 mg daily initially followed by 200 mg daily after week 4)
Study: 33815503
Drug: One-session treatment
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-session treatment group with BioRoot RCS
Study: 33815503
Drug: Two-session treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-session treatment group with BioRoot RCS
Study: 34487844
Drug: Safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil (8 g daily for 12 weeks)
Study: 34747917
Drug: Topical diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diltiazem (diltiazem group)
Study: 34747917
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (placebo group)
Study: 32197107
Drug: Two-dose primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose primary series (days 1 and 91)
Study: 32197107
Drug: One primary
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One primary dose (day 1)
Study: 32197107
Drug: One primary
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One primary dose plus booster (days 1 and 365)
Study: 35545057
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin treatment for 6 weeks
Study: 32706261
Drug: MitoQ (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitoQ (80 mg)
Study: 35001842
Drug: No exercise/no
Approvals — FDA: no, EMA: no, PMDA: no
Description: No exercise/no exposure therapy (control)
Study: 34616808
Drug: Probiotics (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (2 g) added to a low FODMAP diet
Study: 34737837
Drug: Bloodletting at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bloodletting at Shaoshang (LU11) and Shangyang (LI1) acupuncture points, 2-3 ml volume, repeated three times (once daily)
Study: 34558993
Drug: Self-resisted neck
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-resisted neck strength training (3 times weekly for 8 weeks)
Study: 33185628
Drug: Amifampridine (3,4-diaminopyridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifampridine (3,4-diaminopyridine [3,4-DAP]) at a recommended dose of 80 mg a day, divided 3 or 4 times a day.
Study: 32203453
Drug: Luseogliflozin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin 2.5 mg daily (or up to 5 mg daily)
Study: 33847047
Drug: ramipril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril (ACE inhibitor)
Study: 32103567
Drug: Daily surveys
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily surveys assessing PTSD symptoms
Study: 34074291
Drug: Percutaneous periarticular
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous periarticular injection including methylprednisolone, ropivacaine, and epinephrine at 1 day after surgery
Study: 34074291
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional injection (control group)
Study: 35772665
Drug: Placebo (platinum-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (platinum-based chemotherapy)
Study: 35772665
Drug: Olaparib (platinum-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (platinum-based chemotherapy)
Study: 35772665
Drug: Placebo (non-platinum-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (non-platinum-based chemotherapy)
Study: 35772665
Drug: Olaparib (non-platinum-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (non-platinum-based chemotherapy)
Study: 33774848
Drug: Metformin extended-release
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin extended-release 1500 mg daily for 26 weeks
Study: 33501595
Drug: JWH‐018 (75μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: JWH‐018 (75μg/kg bodyweight, average dose 5.52 mg)
Study: 33877876
Drug: Empagliflozin as
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin as an add-on therapy
Study: 33033962
Drug: Ivabradine co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine co-administered with ketoconazole (CYP3A4 inhibitor)
Study: 35460449
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help family-based treatment (GSH-FBT)
Study: 35460449
Drug: Family-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based treatment delivered via videoconferencing (FBT-V)
Study: 35274413
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon beta‐1a (sc IFN β‐1a) 44 μg once or three times weekly
Study: 32024852
Drug: NaHCO3 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 (up to 100 mg·kg‐1)
Study: 33576936
Drug: 165 μg
Normalized name: griseofulvin 165 MG [Fulvicin P/G]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 165 μg PEGylated exenatide
Study: 33576936
Drug: 330 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 330 μg PEGylated exenatide
Study: 33576936
Drug: 660 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 660 μg PEGylated exenatide
Study: 35365535
Drug: Proactive TDM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive TDM combined PK dashboard-driven infliximab dosing
Study: 35365535
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) infliximab therapy
Study: 32332458
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/d for 15 days)
Study: 32332458
Drug: Memantine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10 mg/d for 15 days)
Study: 33152448
Drug: 18 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 doses of 40 mg/m2 of prednisone on alternate days (short arm)
Study: 33152448
Drug: Cumulative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative dose of prednisone tapered over double the time (long arm)
Study: 33152448
Drug: Post-hoc analysis
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-hoc analysis excluding 30 patients treated with low-dose prednisone maintenance therapy
Study: 35622854
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (500,000 IU single oral dose)
Study: 32187881
Drug: Licogliflozin 50
Normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licogliflozin 50 mg twice daily
Study: 32187881
Drug: Licogliflozin 150
Normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licogliflozin 150 mg once daily
Study: 34837648
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone (8 mg once daily)
Study: 34837648
Drug: Intermediate-dose dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose dexamethasone (8 mg twice daily)
Study: 34837648
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (8 mg thrice daily)
Study: 34708640
Drug: Integrated Traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Traditional Chinese and Western Medicine
Study: 34708640
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated according to Western Medicine guidelines
Study: 32186587
Drug: High-Flow Nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Flow Nasal Cannula (HFNC) Oxygen Therapy
Study: 32639389
Drug: Low-dose dexmedetomidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexmedetomidine 0.2 μg·kg‐1 (group LD)
Study: 32639389
Drug: High-dose dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexmedetomidine 0.5 μg·kg‐1 (group HD)
Study: 32971163
Drug: Myrrh extract
Normalized name: myrrh extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrrh extract sitz-bath (10-min, twice a day for 1 week)
Study: 32971163
Drug: Frankincense extract
Normalized name: frankincense extract
DrugBank: Frankincense (DB16592)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frankincense extract sitz-bath (10-min, twice a day for 1 week)
Study: 32971163
Drug: Betadine sitz-bath
Normalized name: SITZ BATH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betadine sitz-bath (10-min, twice a day for 1 week)
Study: 35910688
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (CBT) intervention
Study: 32113466
Drug: Simparica Trio™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simparica Trio™ (1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel)
Study: 32113466
Drug: Sarolaner-alone (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarolaner-alone (1.2 mg/kg)
Study: 32113466
Drug: Moxidectin-alone (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxidectin-alone (24 µg/kg)
Study: 32113466
Drug: Pyrantel-alone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrantel-alone (5 mg/kg)
Study: 36045484
Drug: LY06006 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY06006 (60 mg)
Study: 34463234
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) and sertraline (SERT)
Study: 34463234
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) and pill placebo
Study: 35962142
Drug: Prolonged (week‐long)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged (week‐long) daily administration of the SSRI citalopram
Study: 35962142
Drug: Acute (single‐dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute (single‐dose) administration of the SSRI citalopram
Study: 35545584
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii combined with triple therapy for 14 days and triple therapy for 10 days
Study: 35545584
Drug: Bismuth quadruple
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth quadruple therapy for 10 days
Study: 32118723
Drug: LISA (less
Approvals — FDA: no, EMA: no, PMDA: no
Description: LISA (less invasive surfactant administration via gastric tube)
Study: 34551907
Drug: Hypomethylating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypomethylating agents (Azacitidine and Decitabine)
Study: 34551907
Drug: Investigational agents
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational agents (less active)
Study: 34551907
Drug: Cytostatic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytostatic agents
Study: 34551907
Drug: Agents manipulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agents manipulating pyrimidine metabolism
Study: 32585670
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (pooled treatment groups)
Study: 32941737
Drug: Ketone monoester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone monoester (KME) supplement (0.45 mL/kg)
Study: 32755265
Drug: Cognitive-narrative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-narrative therapy (4 sessions)
Study: 32977253
Drug: AS1000 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS1000 group (L‐arginine, 1 g; folate, 200 μg)
Study: 32977253
Drug: AS2000 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS2000 group (L‐arginine, 2 g; folate, 400 μg; vitamin E, 10 mg)
Study: 32977253
Drug: Global L‐arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Global L‐arginine group (AS1000 and AS2000)
Study: 32977253
Drug: L‐arginine groups
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐arginine groups (AS1000 and AS2000) in male infertility subgroup
Study: 35014217
Drug: GDC-0134 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0134 (up to 1200 mg daily)
Study: 32456442
Drug: EPs 7630,
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPs 7630, 3 × 20 mg/day for 10 days
Study: 32456442
Drug: Amoxicillin, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, 3 × 500 mg/day for 10 days
Study: 36602846
Drug: Relapse prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse prevention treatment
Study: 32152813
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA) 3.0 g via subfascial drain
Study: 32152813
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) 1.5 g just before wound closure
Study: 32152813
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and IV TXA
Study: 32000724
Drug: HAI oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HAI oxaliplatin plus systemic FOLFIRI plus targeted therapy (anti-EGFR antibody or bevacizumab)
Study: 32000724
Drug: Conventional systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional systemic chemotherapy (sys-CT) plus targeted therapy (anti-EGFR or antiangiogenic antibody)
Study: 35409483
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support plus daily text messages
Study: 35409483
Drug: Daily supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supportive text messages only
Study: 33412465
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg twice daily and pembrolizumab 2 mg/kg every 3 weeks
Study: 35509077
Drug: NTHi-Mcat vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTHi-Mcat vaccine (0-2-6 months)
Study: 35509077
Drug: NTHi-Mcat vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTHi-Mcat vaccine (0-2-12 months)
Study: 35509077
Drug: NTHi-Mcat vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTHi-Mcat vaccine (both schedules)
Study: 34262664
Drug: Developmentally adapted
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Developmentally adapted cognitive processing therapy (D-CPT)
Study: 36641898
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lapatinib and trastuzumab
Study: 32869586
Drug: Interaction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interaction of twelve meridian muscle regions and contralateral needling therapy
Study: 32869586
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of mecobalamine and oral citicoline sodium capsules
Study: 32366139
Drug: Industrial beer
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Industrial beer (4.5% alcohol), 330 ml daily for 3 weeks
Study: 32366139
Drug: Craft beer
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craft beer (9% alcohol), 330 ml daily for 3 weeks
Study: 35915802
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition support on a routine basis
Study: 32716291
Drug: Rizatriptan oral
Normalized name: rizatriptan Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan oral gel (test)
Study: 32716291
Drug: Rizatriptan oral
Normalized name: rizatriptan Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan oral lyophilisate (reference)
Study: 33728385
Drug: Aayudh Advance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aayudh Advance (herbal formulation)
Study: 33728385
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care treatment
Study: 36056399
Drug: Robotic walking
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic walking rehabilitation treatment (experimental group)
Study: 36056399
Drug: Conventional gait
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional gait rehabilitation treatment (control group)
Study: 35810173
Drug: Gratitude expression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gratitude expression treatment (GET)
Study: 33221898
Drug: Antimicrobial prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial prescriptions during inpatient admissions
Study: 33221898
Drug: Antimicrobial prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial prescriptions in neonatal sepsis
Study: 33221898
Drug: Antimicrobial prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial prescriptions in lower respiratory tract infection (LRTI)